Sigal Charles Elliott
- SEC CIK
- 0001661908
No open-market purchases or sales filed in the past year.
Current role at each company
- VIR Vir Biotechnology, Inc.Directoras of May 28, 2026
- ALNY Alnylam Pharmaceuticals, Inc.Directoras of May 22, 2026
- SURF Surface Oncology, Inc.Directoras of Sep 8, 2023
- ADAPY Adaptimmune Therapeutics PLCDirectoras of Jul 3, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Sigal Charles Elliott as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VIR Vir Biotechnology, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2023 (view filing) | Jan 3-4 | 2 days | Sigal Charles ElliottDirector | PPurchase | +5.00K | $25.43 | +$127.1K | New position5.00K after | 2 lots |
| Jan 9, 2023 (view filing) | Jan 5 | 4 days | Sigal Charles ElliottDirector | PPurchase | +2.50K | $24.96 | +$62.4K | +50.0%7.50K after | |
| Mar 2, 2023 (view filing) | Mar 1 | 1 day | Sigal Charles ElliottDirector | PPurchase | +2.50K | $22.73 | +$56.8K | +33.3%10.0K after |